We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| E-therapeutics Plc | LSE:ETX | London | Ordinary Share | GB00B2823H99 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.425 | 4.63% | 9.60 | 9.40 | 9.80 | 9.40 | 9.00 | 9.00 | 2,228,014 | 16:35:08 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 475k | -8.27M | -0.0142 | -6.62 | 54.88M |
From Apr 2019 to Apr 2024
TIDMETX
RNS Number : 2414G
e-Therapeutics plc
25 May 2017
E-THERAPEUTICS PLC
("e-Therapeutics" or the "Company")
NOTIFICATION BY DIRECTOR
Oxford, UK, 25 May 2017 - e-Therapeutics plc (AIM: ETX), the drug discovery company, announces that it was informed on 25 May 2017 by the Company's Chairman, Mr Iain Ross, that on the afternoon of 24 May 2017, Redx Pharma plc ("Redx"), the drug discovery and development company, announced that it had gone into administration.
Redx's shares were suspended from trading on AIM as at 4.35pm yesterday afternoon. Mr Ross was appointed Chairman of Redx on 1 May 2017.
This announcement is being made pursuant to the requirements of AIM Rule 17 and Schedule 2(g)(v) to the AIM Rules for Companies.
For further information, please contact:
Contacts:
e-Therapeutics plc Tel: +44 (0) 1993 Ray Barlow, CEO 883 125 Steve Medlicott, Finance www.etherapeutics.co.uk Director Numis Securities Limited Tel: +44 (0) 207 Michael Meade / Freddie 260 1000 Barnfield www.numis.com (Corporate Finance) James Black (Corporate Broking) Instinctif Partners Tel: +44 (0) 207 Melanie Toyne-Sewell / 457 2020 Alex Shaw Email: e-therapeutics@instinctif.com
About e-Therapeutics plc
e-Therapeutics is a drug discovery company with a unique and proprietary in silico discovery platform. The Company is applying its computational platform to the discovery of new drug candidates for which it can secure robust intellectual property rights.
The therapeutic focus of the Company's discovery activity is in areas of complex disease with unmet medical need, including immuno-oncology. The business model is to partner these preclinical drug candidates.
e-Therapeutics is headquartered in Oxford. For more information about the Company please visit www.etherapeutics.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAOKPDDKBKDAPB
(END) Dow Jones Newswires
May 25, 2017 06:20 ET (10:20 GMT)
1 Year E-therapeutics Chart |
1 Month E-therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
